Edwards Lifesciences (EW) Stock Price, News & Analysis

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 1 sell rating, 6 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EW shares.
View EW analyst ratings or view top-rated stocks.

17 brokers have issued 12 month price targets for Edwards Lifesciences' shares. Their EW share price targets range from $57.00 to $107.00. On average, they predict the company's stock price to reach $91.73 in the next year. This suggests a possible upside of 5.2% from the stock's current price.
View analysts price targets for EW or view top-rated stocks among Wall Street analysts.

Edwards Lifesciences' stock was trading at $76.25 at the start of the year. Since then, EW stock has increased by 14.4% and is now trading at $87.24.
View the best growth stocks for 2024 here.

Edwards Lifesciences saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 10,450,000 shares, an increase of 23.8% from the February 29th total of 8,440,000 shares. Based on an average daily trading volume, of 3,940,000 shares, the short-interest ratio is currently 2.7 days. Currently, 1.8% of the shares of the company are sold short.
View Edwards Lifesciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our EW earnings forecast.

Edwards Lifesciences will be holding an earnings conference call on Thursday, April 25th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

Edwards Lifesciences Co. (NYSE:EW) posted its quarterly earnings data on Tuesday, February, 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.64. The medical research company had revenue of $1.53 billion for the quarter, compared to analysts' expectations of $1.50 billion. Edwards Lifesciences had a trailing twelve-month return on equity of 23.56% and a net margin of 23.35%. The firm's revenue was up 13.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.64 EPS.
Read the conference call transcript.

ETFs with the largest weight of Edwards Lifesciences (NYSE:EW) stock in their portfolio include iShares U.S. Medical Devices ETF (IHI), Fundamentals First ETF (KNOW), Global X Aging Population ETF (AGNG), IQ Winslow Focused Large Cap Growth ETF (IWFG), Fidelity Disruptive Medicine ETF (FMED), First Trust Indxx Medical Devices ETF (MDEV), Strategas Global Policy Opportunities ETF (SAGP) and BNY Mellon Sustainable US Equity ETF (BKUS).

Edwards Lifesciences shares split on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly created shares were issued to shareholders after the market closes on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

Edwards Lifesciences updated its first quarter 2024 earnings guidance on Tuesday, February, 6th. The company provided earnings per share guidance of 0.620-0.660 for the period, compared to the consensus estimate of 0.660. The company issued revenue guidance of $1.5 billion-$1.6 billion, compared to the consensus revenue estimate of $1.6 billion.

389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

Edwards Lifesciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Factory Mutual Insurance Co. (0.08%), Sarasin & Partners LLP (0.04%), Gateway Investment Advisers LLC (0.03%), West Coast Financial LLC (0.02%), Beese Fulmer Investment Management Inc. (0.02%) and AMF Tjanstepension AB (0.02%). Insiders that own company stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daniel J Lippis, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem.
View institutional ownership trends.

Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.